The Interaction of CX3CL1 and CX3CR1 in Infection, Inflammation, and Cancer: Implications for Therapeutic Intervention Volume 61- Issue 4

Jeyatheepan Jeyaretnam*

• Department of General Medicine, Instrumental Lymph Drainage Approaches, Switzerland

Received: April 14, 2025; Published: April 24, 2025

*Corresponding author: Jeyatheepan Jeyaretnam, Department of General Medicine, Instrumental Lymph Drainage Approaches, Switzerland

DOI: 10.26717/BJSTR.2025.61.009612

Abstract PDF

Chemokines and their receptors play a pivotal role in modulating immune responses during infection, inflammation, and cancer. The CX3CL1/CX3CR1 axis, characterized by the interaction between the chemokine CX3CL1 (Fractalkine) and its receptor CX3CR1, has emerged as a critical pathway in these biological processes. This paper explores the molecular mechanisms of CX3CL1/CX3CR1 interaction and its influence on immune cell recruitment, tissue remodelling, and tumour progression. In the context of infection and inflammation, this pathway contributes to both protective and pathological immune responses. Moreover, CX3CL1/CX3CR1 signalling has been implicated in the metastatic spread of cancers. The therapeutic potential of targeting the CX3CL1/CX3CR1 interaction in these diseases is discussed, along with current challenges and future directions.

1. CX3CL1 (Fractalkine): A unique chemokine that exists both as a membrane-bound protein and a soluble chemokine. It is primarily involved in immune cell recruitment and adhesion to endothelial cells.

2. CX3CR1: The receptor for CX3CL1, expressed on various immune cells including monocytes, macrophages, dendritic cells, and microglia.

3. Function in Immune Response: The CX3CL1/CX3CR1 axis is crucial for maintaining immune homeostasis, mediating the recruitment of immune cells to sites of infection, and modulating tissue responses in inflammation and cancer. (Combadière C, et al. [1,2]).

CX3CL1 and CX3CR1 in Infection

a. Role in Immune Cell Recruitment: The CX3CL1/CX3CR1 axis helps recruit monocytes, T-cells, and other immune cells to sites of infection, particularly in viral and bacterial diseases.

b. Regulation in Viral Infections: CX3CL1 is upregulated during viral infections like HIV and influenza, promoting the migration of immune cells to infected tissues.

c. Bacterial Infections: In certain bacterial infections, CX3CL1 may play a role in controlling pathogen spread by facilitating macrophage and neutrophil accumulation (Papadopoulos P, et al. [3,4]).

CX3CL1 and CX3CR1 in Inflammation

a. Chronic Inflammation: Persistent activation of the CX3CL1/ CX3CR1 axis in conditions such as atherosclerosis, rheumatoid arthritis, and inflammatory bowel disease (IBD) leads to chronic inflammation.

b. Tissue Remodelling and Inflammatory Diseases: This pathway regulates tissue remodelling by inducing the release of pro-inflammatory cytokines and mediators.

c. CX3CL1/CX3CR1 in Neuroinflammation: The CX3CL1/CX- 3CR1 axis is critical in neuroinflammatory diseases, such as Alzheimer’s disease, where it influences microglial activation and neuronal damage (Figure 1).

Figure 1

CX3CL1 and CX3CR1 in Cancer

1. Tumor Progression and Metastasis: The CX3CL1/CX3CR1 pathway plays a role in promoting tumor growth and metastasis by facilitating the infiltration of immune cells into the tumor microenvironment.

2. Immune Escape: Tumors may exploit the CX3CL1/CX3CR1 axis to evade immune surveillance by attracting immune suppressor cells like regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs).

3. CX3CR1 as a Target in Cancer Therapy: Targeting CX3CL1/ CX3CR1 could be a novel strategy to block tumor cell migration or enhance anti-tumor immune responses (Tominari Y, et al. (2014), Hwang M, et al. (2018)).

Therapeutic Potential and Future Directions

a. Therapeutic Targeting of CX3CL1/CX3CR1: Strategies for blocking CX3CL1/CX3CR1 interaction, either through monoclonal antibodies or small molecules, have shown promise in preclinical studies.

b. Challenges: The complex role of CX3CL1/CX3CR1 in both promoting immune responses and suppressing inflammation makes its therapeutic targeting challenging. Balance must be maintained between anti-inflammatory and immune-boosting actions.

c. Future Directions: Exploration of CX3CL1/CX3CR1 in personalized medicine and combination therapies for cancer, infection, and chronic inflammatory diseases (Tan X, et al. [5,6]).

The CX3CL1/CX3CR1 interaction is central to immune responses in infection, inflammation, and cancer. Its role in both protective immunity and pathological conditions underscores the complexity of this pathway. Although targeting this axis holds significant therapeutic potential, further research is needed to refine strategies that can modulate its activity in various diseases [7,8].

1. Combadière C, et al. (1998) Identification of CX3CR1, a chemokine receptor for fractalkine, by functional expression cloning. J Biol Chem 273(44): 22820-22826.
2. Imai T, et al. (1997) Identification and characterization of fractalkine receptor CX3CR1, which mediates both adhesion and chemotaxis. J Biol Chem 272(25): 15309-15315.
3. Papadopoulos P, et al. (2011) CX3CL1 and its receptor CX3CR1 in the pathogenesis of infectious diseases. J Infect Dis 204(6): 963-974.
4. Sallusto F, et al. (2000) The role of CX3CR1 in the recruitment of memory T cells to inflamed tissues. J Immunol 164(3): 2075-2081.
5. Tan X, et al. (2020) Therapeutic targeting of CX3CR1 in cancer and inflammation. Pharmacol Ther 206: 107439.
6. Shimizu T, et al. (2018) CX3CR1 antagonism in cancer immunotherapy. J Immunotherapy Cancer 6(1): 65.
7. McGill M, et al. (2015) CX3CR1-mediated recruitment of macrophages and T cells in chronic inflammatory disease. Immunology 145(3): 233-243.
8. Henkel J, et al. (2019) Fractalkine/CX3CR1 axis in the pathogenesis of neurodegenerative diseases. J Neuroimmunol 321: 12-23.